Rigel Pharmaceuticals has completed the transfer of the New Drug Application (NDA) for Gavreto to its partner, Sanofi, in June 2024 [1]. This transfer signifies Rigel's transition out of the commercialization of Gavreto.
What does this NDA transfer mean for Gavreto?
The transfer of the New Drug Application (NDA) means that Sanofi will now be responsible for the commercialization and related activities for Gavreto [1]. Rigel will receive an upfront payment of $50 million from Sanofi and is eligible for additional milestone payments totaling up to $100 million, as well as royalties on future sales [1].
What is Gavreto approved for?
Gavreto (pralsetinib) is an oral selective RET inhibitor approved for the treatment of adult patients with:
* Metastatic non-small cell lung cancer (NSCLC) whose tumors are RET fusion-positive [2].
* Metastatic RET fusion-positive thyroid cancer [2].
What is the timeline for Rigel's involvement with Gavreto after the transfer?
Following the NDA transfer, Rigel will provide support to Sanofi for a limited transition period [1]. After this period, Sanofi will assume full responsibility for the drug [1].
What are the financial implications for Rigel?
Rigel received an upfront payment of $50 million from Sanofi upon completion of the NDA transfer [1]. The company is also eligible for up to $100 million in additional milestone payments and royalties on future sales of Gavreto [1]. This transaction is intended to strengthen Rigel's financial position, allowing it to focus on its internal pipeline, including fostamatinib and its oncology candidates [1].
Who is Sanofi and what is their role?
Sanofi is a global pharmaceutical company that partnered with Rigel for the development and commercialization of Gavreto [1]. With the NDA transfer, Sanofi is now the primary entity responsible for the marketing and sales of Gavreto in the United States [1].
What are the implications for patients currently taking Gavreto?
Patients who are currently being treated with Gavreto should not experience any disruption in their treatment due to this transfer [1]. Sanofi will continue to make Gavreto available to patients [1].
What is Rigel's future focus after this transfer?
Rigel will now concentrate its resources on advancing its internal pipeline, including fostamatinib (Tavalisse) and its oncology pipeline candidates [1]. This strategic shift aims to maximize shareholder value by prioritizing Rigel's wholly-owned assets [1].
What are the patent details for Gavreto?
Information regarding the specific patents covering Gavreto and their expiration dates is available through resources like DrugPatentWatch.com [3]. Understanding these patents is crucial for assessing market exclusivity and the potential for generic or biosimilar competition.
How does this transfer affect the competitive landscape for lung and thyroid cancer treatments?
The commercialization of Gavreto by Sanofi will continue to position it within the competitive landscape of targeted therapies for RET fusion-positive NSCLC and thyroid cancer. The availability of effective treatments like Gavreto is important for patients with these specific genetic alterations.
Sources:
[1] https://www.rigel.com/news-releases/news-release-details/rigel-completes-transfer-gavreto-nda-sanofi-and-receives-50-million
[2] https://www.gavreto.com/
[3] https://drugpatentwatch.com/